Clinical Trial

ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess pharmacokinetic parameters of atorvastatin at different doses when combined with the standard first line tuberculosis (TB) treatment regimen in adults with drug sensitive pulmonary TB. The pharmacokinetics parameters will be correlated with Pharmcodynamic measures and a PK/PD model that will identify an optimal dosing regimen of atorvastatin that is appropriate for the treatment of pulmonary tuberculosis will be developed.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-18; most recent amendment 2026-01-21.
Status change: Not Yet Recruiting → Recruiting 2026-01-17
Trial Details
NCT Number NCT07303699
Lead Sponsor Obafemi Awolowo University Teaching Hospital
Collaborators: Open Philanthropy, Obafemi Awolowo University
Conditions Pulmonary Tuberculosis (TB)
Enrollment 80 participants
Start Date 2026-01-03
Primary Completion 2027-03-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-23